# U.S. Venture Partners

> U.S. Venture Partners is a VC fund backing Software and Health Care. See 427 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 427
- Last investment: Jun 2026
- Lead investor: 33%
- Last fund: Dec 2022
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/57330
- X (Twitter): http://twitter.com/USVP_
- Website: http://usvp.com
- Facebook: http://www.facebook.com/US-Venture-Partners-USVP/113779035

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the pastthirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

## Contacts

5 contacts available for U.S. Venture Partners. Shizune tracks 9 team members at U.S. Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/us-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5M–$42M |
| Series B | $7M–$51M |
| Series C | $7.8M–$68M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 61 | 14% |
| Health Care | 51 | 12% |
| Information Technology | 32 | 7% |
| Medical | 28 | 7% |
| Manufacturing | 27 | 6% |

213 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 100 | 23% |
| Series C | 80 | 19% |
| Series A | 71 | 17% |
| Funding Round | 52 | 12% |
| Series D | 35 | 8% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 197 | 46% |
| Israel | 13 | 3% |
| Canada | 3 | 1% |
| France | 2 | 0% |
| China | 1 | 0% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Phil Young | Senior Advisor | 9 | https://shizune.co/investors/profile/phil-young |
| Casey Tansey | General Partner | 24 | https://shizune.co/investors/profile/casey-tansey |
| Dafina Toncheva | General Partner | 36 | https://shizune.co/investors/profile/dafina-toncheva |
| Dale Holladay | CPA/CFO | 0 | https://shizune.co/investors/profile/dale-holladay |
| Jacques Benkoski | General Partner | 20 | https://shizune.co/investors/profile/jacques-benkoski |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Maneva | Maneva develops video-to-action artificial intelligence systems for manufacturing environments, using computer vision and deep learning to analyze production processes and support operational decision-making in real time. Its platform helps manufacturers address quality assurance, downtime reduction, productivity monitoring, and workplace safety byconverting visual data from factory-floor cameras into actionable insights and automated responses. The company offers solutions such as VITA for defect detection, product verification, and equipment monitoring, as well as ALIS, an AI-powered line supervision system that tracks production efficiency and safety compliance. Maneva's technology is designed to work with existing camera infrastructure and can be applied across industries, including food and beverage, pharmaceuticals, electronics, automotive, steel, and distribution operations. The company focuses on helping manufacturers improve production consistency, identify operational issues, and monitor factory processes through AI-driven visual analysis. | $27M | Series A | Jun 10, 2026 |  |
| Cagent Vascular | Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $41M | Series D | May 19, 2026 |  |
| Nervonik | Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M | Series B | Apr 27, 2026 |  |
| Route 92 Medical | Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M | Private Equity | Apr 07, 2026 |  |
| Slang | Slang.ai is a digital phone concierge that answers questions, takes reservations, and satisfies callers. | $28M | Series B | Feb 24, 2026 |  |
| Adaptive6 | Adaptive6 is a Cloud Cost Governance platform that addresses both cloud and code, providing a comprehensive approach to managing costs effectively. The platform empowers engineers to take immediate action on cloud costs and prevents waste at the code level, enhancing efficiency in cloud management. | $28M | Series A | Jan 28, 2026 |  |
| Okami Medical | Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. | $45M | Series F | Nov 19, 2025 |  |
| Apono | Apono helps companies become secure and compliant while maintaining their productivity and agility. The company aims to simplify how teams manage access to critical systems by automating the provisioning and deprovisioning of permissions based on real-time needs, ensuring only the right people have access at the right time. | $34M | Series B | Nov 18, 2025 |  |
| Weave | Weave provides an artificial intelligence collaboration platform for biomedicine. The company is headquartered in the United States. | $20M | Series A | Oct 16, 2025 |  |
| Sparrow Pharmaceuticals | Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with currentoptions. Its lead product, clofutriben, is an oral, small molecule, designed to target the source of active intracellular cortisol in key tissues.The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States. | $95M | Series B | Sep 24, 2025 |  |

10 of 427 investments shown.

## Co-investors
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 27 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 19 deals together
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 19 deals together
- [Mayfield Fund](https://shizune.co/investors/profile/mayfield-fund) — VC Fund, 17 deals together
- [Battery Ventures](https://shizune.co/investors/profile/battery-ventures) — VC Fund, 15 deals together
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 14 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Medical Device Investors](https://shizune.co/investors/medical-device-investors)
- [Medical Device VC Funds](https://shizune.co/investors/medical-device-vc-funds)
- [Medical Device Investors in United States](https://shizune.co/investors/medical-device-investors-united-states)
- [Medical Device VC Funds in United States](https://shizune.co/investors/medical-device-vc-funds-united-states)
- [Manufacturing Investors in United States](https://shizune.co/investors/manufacturing-investors-united-states)
- [Manufacturing VC Funds in United States](https://shizune.co/investors/manufacturing-vc-funds-united-states)

## FAQ

### What does U.S. Venture Partners invest in?

U.S. Venture Partners invests primarily in Software, Health Care and Information Technology startups, most often at Series B and Series C stage. Most of the 427 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is U.S. Venture Partners's check size?

U.S. Venture Partners typically joins rounds of $5M–$42M at Series A, $7M–$51M at Series B and $7.8M–$68M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds U.S. Venture Partners participates in.

### How do I contact U.S. Venture Partners?

Public channels for U.S. Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at U.S. Venture Partners?

The team at U.S. Venture Partners includes Phil Young (Senior Advisor), Casey Tansey (General Partner) and Dafina Toncheva (General Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co